Last 12.15 NOK
Change Today -1.35 / -10.00%
Volume 63.7K
NAVA On Other Exchanges
Symbol
Exchange
Berlin
As of 10:25 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

navamedic (NAVA) Snapshot

Open
13.00 NOK
Previous Close
13.50 NOK
Day High
13.40 NOK
Day Low
11.15 NOK
52 Week High
11/4/13 - 18.10 NOK
52 Week Low
09/19/13 - 10.25 NOK
Market Cap
104.0M
Average Volume 10 Days
17.0K
EPS TTM
-0.21 NOK
Shares Outstanding
8.6M
EX-Date
05/7/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NAVAMEDIC (NAVA)

Related News

No related news articles were found.

navamedic (NAVA) Related Businessweek News

No Related Businessweek News Found

navamedic (NAVA) Details

Navamedic ASA, a pharmaceutical company, in-licenses, buys, and markets pharmaceuticals and other health care products in Norway and internationally. Its product portfolio includes original and generic pharmaceuticals, as well as food supplements, medical devices, and other health care products. The company also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, tyrosinemia, maple sirup urine disease, homocystinuria, methylmalonic acidemia, propionic acidemia, and glutaric aciduria type 1, as well as carbohydrate metabolism, fat metabolism, and renal diseases. In addition, it sells consumer care products, including non-prescription pharmaceuticals primarily through pharmacies and/or drugstores. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Lysaker, Norway.

Founded in 2002

navamedic (NAVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

navamedic (NAVA) Key Developments

Navamedic ASA Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Second Half of 2014

Navamedic ASA reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, operating revenues were NOK 59,478,000 against NOK 38,126,000 for the same period in the last year. EBITDA was NOK 3,026,000 against NOK 808,000 for the same period in the last year. Operating results (EBIT) was NOK 1,114,000 against operating loss (LBIT) of NOK 872,000 for the same period in the last year. Ordinary results before tax were NOK 233,000 against ordinary loss before tax of NOK 1,147,000 for the same period in the last year. Net profit was NOK 399,000 against net loss of NOK 496,000 for the same period in the last year. Net cash inflow from operations was NOK 794,000 against NOK 2,187,000 for the same period in the last year. Purchase of intangible assets was NOK 424,000 against NOK 1,617,000 for the same period in the last year. Diluted earnings per share were NOK 0.05 against diluted loss per share of NOK 0.06 for the same period in the last year. For the six months, operating revenues were NOK 102,356,000 against NOK 72,130,000 for the same period in the last year. EBITDA was NOK 5,004,000 against NOK 4,304,000 for the same period in the last year. Operating result (EBIT) was NOK 1,133,000 against NOK 1,166,000 for the same period in the last year. Ordinary result before tax was NOK 451,000 against NOK 729,000 for the same period in the last year. Net profit was NOK 408,000 against NOK 905,000 for the same period in the last year. Net cash out flow from operations was NOK 533,000 against net cash out flow from operations of NOK 7,450,000 for the same period in the last year. Purchase of intangible assets was NOK 628,000 against NOK 1,900,000 for the same period in the last year. Diluted earnings per share were NOK 0.05 against NOK 0.10 for the same period in the last year. The company forecasts continued sales growth in the second half of 2014, both organically and through the addition of new products. The company expects profitability to further improve throughout the year 2014.

Navamedic ASA to Report Q2, 2014 Results on Aug 22, 2014

Navamedic ASA announced that they will report Q2, 2014 results on Aug 22, 2014

Navamedic ASA Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Financial Guidance for the Year 2014

Navamedic ASA reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported operating revenues were NOK 42,878,000 against NOK 34,004,000 a year ago. EBITDA was NOK 1,979,000 against NOK 3,496,000 a year ago. Operating result (EBIT) was NOK 19,000 against NOK 2,039,000 a year ago. Ordinary result before tax was NOK 217,000 against NOK 1,876,000 a year ago. Net profit was NOK 9,000 or NOK 0.00 per diluted share against NOK 142,000 or NOK 0.16 per diluted share a year ago. Net cash used in operations was NOK 241,000 against net cash flow from operations of NOK 486,000 a year ago. Purchase/disposal of intangible assets was NOK 204,000 against NOK 283,000 a year ago. EBITDA for the first quarter 2013 came in at NOK 2.0 million, compared to NOK 3.5 million last year. However, the 2013 first quarter saw a NOK 2.6 million one-of royalty payment, originating from Navamedic's sale of its Glucomed business in 2009. Adjusted for this factor, the underlying profitability from operations saw an improvement in the first quarter 2014 compared to the same period last year. Navamedic expects a continued sales growth also in 2014, however not at the extreme rate seen in the last two years. Navamedic expects the EBITDA margin to further improve throughout 2014. The Company's target is to deliver positive earnings before taxes in every quarter going forward.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVA:NO 12.15 NOK -1.35

NAVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NAVA.
View Industry Companies
 

Industry Analysis

NAVA

Industry Average

Valuation NAVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book 1.0x
Price/Cash Flow 20.1x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVAMEDIC, please visit www.navamedic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.